Skip to main content
SDGR
NASDAQ Life Sciences

Schrödinger 10-Q: Q3 Revenue Up 19% to $64.5M, $373M Cash, Novartis Deal Amended

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$31.439
Mkt Cap
$2.133B
52W Low
$10.945
52W High
$33.78
52W Position info
187% above low
Off High info
6.9% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

SDGR has more than doubled off its 52-week low of $10.945.

Summary

Schrödinger's Q3 10-Q shows revenue up 19% to $64.5M with drug discovery nearly doubling, a wider net loss driven by a non-cash investment markdown, and $373.4M in cash funding at least 24 months of operations.


Key Events · Earnings and Guidance · SDGR

  • Q3 Revenue Grows 19% to $64.5M

    Total revenue rose to $64.5M from $54.3M, with drug discovery revenue nearly doubling to $24.2M from $13.0M on a $12.0M Structure Therapeutics collaboration milestone.

  • Net Loss Widens on Non-Cash Mark

    Net loss was $37.7M versus $32.8M, driven by a $14.8M non-cash change in fair value of equity investments (Structure Therapeutics); operating loss narrowed to $26.1M from $45.9M as opex fell 13% to $64.4M.

  • $373.4M Cash, 24-Month Runway

    Cash, cash equivalents, restricted cash and marketable securities totaled $373.4M at September 30, 2026, which management says funds operations for at least the next 24 months; nine-month operating cash use was $96.5M.

  • Novartis Collaboration Amended

    A September 14, 2026 amendment replaces certain collaboration programs with two new programs; total eligible milestones remain up to $1.424B ($704.0M discovery/development, $720.0M commercial).


Analysis · SDGR · Life Sciences

Full financials behind the same-day earnings 8-K confirm Q3 revenue of $64.5M (+19%), with drug discovery revenue nearly doubling to $24.2M on a $12.0M Structure Therapeutics milestone. The headline net loss widened to $37.7M from $32.8M, but that reflects a $14.8M non-cash mark-to-market swing on the Structure Therapeutics stake rather than operating deterioration; operating expenses actually fell 13% to $64.4M and the operating loss narrowed to $26.1M from $45.9M. With cash and securities of $373.4M, the company funds at least 24 months of operations, so there is no near-term financing need despite $96.5M of operating cash burned in nine months. Two new disclosures matter for the pipeline: the September Novartis amendment swaps certain programs for two new ones while keeping up to $1.424B in milestones, and the Tectora out-licensing of two early-stage programs brought an equity stake rather than cash.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SDGR was trading at $31.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.95 to $33.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SDGR - Latest Insights

SDGR
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.50
Real-time Price: $22.90 info
Change: -$6.60 (-22%) info
Market Cap: $1.722B info
SDGR
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.75
Real-time Price: $22.90 info
Change: -$7.85 (-26%) info
Market Cap: $1.722B info
SDGR
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $28.72
Real-time Price: $22.90 info
Change: -$5.82 (-20%) info
Market Cap: $1.722B info
SDGR
Sep 09, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.03
Real-time Price: $22.90 info
Change: +$2.87 (+14%) info
Market Cap: $1.722B info
SDGR
Aug 05, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $15.71
Real-time Price: $22.90 info
Change: +$7.19 (+46%) info
Market Cap: $1.722B info